Evaluation of Protein in the Urine in Patients Receiving Bevacizumab
- Conditions
- Colon CancerRectal Cancer
- Registration Number
- NCT00849394
- Lead Sponsor
- North Texas Veterans Healthcare System
- Brief Summary
This is a clinical research study to look at the incidence of proteinuria (a condition in which urine contains an abnormal amount of protein) caused by shortened infusions (given into the vein over 10 or 15 minutes) of bevacizumab (a medication prescribed for colon, lung, or breast cancer). There are currently no published studies or clinical data looking at how safe shortened infusions of bevacizumab are in relationship to the side effect of proteinuria. We hypothesis that shortened infusions of bevacizumab will result in an increased risk for proteinuria compared to the standard infusions of this agent.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 106
- Patients must be 18 years older
- Patients must be receiving his/her first dose of bevacizumab
- Patients must sign an informed consent
- Patients receiving > 10 mg/kg doses of bevacizumab
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method To evaluate the effect of shortened infusions (0.5 mg/kg/min) of bevacizumab on the incidence of proteinuria. 3-6 months
- Secondary Outcome Measures
Name Time Method To evaluate the time (number of days) to the incidence of proteinuria with shortened infusions of bevacizumab AND to evaluate the effect of controlled versus uncontrolled hypertension and the incidence of proteinuria. 3-6 months
Trial Locations
- Locations (3)
VA North Texas Health Care System
🇺🇸Dallas, Texas, United States
UT Southwestern Medical Center
🇺🇸Dallas, Texas, United States
Parkland Health and Hospital System
🇺🇸Dallas, Texas, United States